Stay updated on XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial
Sign up to get notified when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.

Latest updates to the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check21 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.SummaryDifference2%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check50 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check65 days agoChange DetectedThe web page has undergone significant updates regarding a clinical study on XMT-1592, specifically changing the focus from a Phase 1b trial to an open-label, dose escalation study targeting patients with platinum-resistant ovarian cancer and non-squamous NSCLC. Key details about the study's design, including the maximum tolerated dose (MTD) confirmation process and the inclusion of collaborators, have been clarified.SummaryDifference34%
Stay in the know with updates to XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.